We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
- Authors
Hee Yeon Lee; Ji Hyung Hong; Jae Ho Byun; Hee-Jun Kim; Sun Kyung Baek; Jin Young Kim; Ki Hyang Kim; Jina Yun; Jung A. Kim; Kwonoh Park; Hyo Jin Lee; Jung Lim Lee; Young-Woong Won; Il Hwan Kim; Woo Kyun Bae; Kyong Hwa Park; Der-Sheng Sun; Suee Lee; Min-Young Lee; Guk Jin Lee
- Abstract
Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease < 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
- Subjects
SOUTH Korea; CA 125 test; OVARIAN epithelial cancer; ADJUVANT treatment of cancer; OVARIAN cancer; CANCER cells; BIOMEDICAL materials; MEDICAL records
- Publication
Cancer Research & Treatment, 2020, Vol 52, Issue 1, p277
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2019.292